Indeed, this was further supported by the observation that ER-negative tumours maintained the methylation status of ESR1 gene (encodes ERα) promoter, but not in ER-positive tumours implying that Me is the potential contributing factor for ER negativity in breast cancers [70]. This evidence concerns the gene ESR1 and breast carcinoma.